Course and prognosis of myasthenia gravis: a systematic review

@article{Mao2010CourseAP,
  title={Course and prognosis of myasthenia gravis: a systematic review},
  author={Zhi-Feng Mao and Xue-an Mo and Chao Qin and Yong‐Rong Lai and T. C. Olde Hartman},
  journal={European Journal of Neurology},
  year={2010},
  volume={17}
}
The clinical course of myasthenia gravis (MG) is variable, and spontaneous remission is still uncommon. Knowledge of the prognostic factors may help understand the course of MG and thus optimize its management. A systematic review search was conducted in MEDLINE and EMBASE for English language studies from 1985 through 2009. We identified additional studies by reviewing bibliographies of retrieved articles and hand search main journal of neurology. Studies evaluating variables associated with… 

Prognostic factors of remission in myasthenia gravis after thymectomy.

Patients with mild disease preoperatively may have a better chance of remission of MG after thymectomy, and studies which evaluated variables associated with, or predictive of, remission in adult myasthenic patients after thye surgery showed the most consistent association with remission.

Low-Dose Medication and Long-Term Outcome in Myasthenia Gravis

Most patients with MG will realize disease stability characterized by either remission or MM status, and the MGFA class at year 3 of diagnosis is a clinical predictor of long-term disease prognosis.

Factors affecting outcome in myasthenia gravis

Prognosis is favorable for the majority of myasthenia gravis patients, regardless of age, maximum disease severity, or antibody status, according to Muscle Nerve 54.

Disease severity and response to treatment in Iranian patients with myasthenia gravis

The overall outcome was favorable in the majority of patients, despite differences in the disease course and severity, and contrary to the previous reports, anti-MuSK positive patients in this series did not need a more vigorous treatment regimen comparing other serologic subtypes of MG.

Frequency and clinical features of treatment-refractory myasthenia gravis

A small subgroup of patients with generalized myasthenia gravis do not respond sufficiently to standard therapies and are at higher risk for a refractory course, highlighting an unmet need for new treatment options.

Start high, then go low: An effective strategy in the treatment of myasthenia gravis

A retrospective study of 688 consecutive patients diagnosed with generalized MG at 13 centers across Japan, the authors evaluated outcomes of MG patients treated with EFT vs. those treated in a more conventional manner and found that lower dose regimens are likely preferable given the lower probability of side effects.

Surgical management prospects for myasthenia gravis in Nigeria: A preliminary report of Enugu experience

Thymectomy appears to improve the prognosis of MG in the local setting of Enugu, Nigeria, as indicated by the general outcome of MG patients following thymectomy, which was favorable.

Clinical predictors for the prognosis of myasthenia gravis

Occurrence of associated autoimmune disease can serve as a potential predictor for myasthenia gravis relapse and either ptosis or diplopia, as well as thymic hyperplasia can predict generalization in the first six months.

Thymic pathological examination of non-thymomatous myasthenia gravis patients: A pilot study for prediction of outcome

This pilot study was an attempt to discover any prognostic indices from the histopathological examination of the resected thymic tissue in the patients with myasthenia gravis.

References

SHOWING 1-10 OF 46 REFERENCES

Prognosis of myasthenia gravis: A multicenter follow-up study of 844 patients

Prognosis of myasthenia gravis: a retrospective study of 380 patients

Early diagnosis was associated with a better prognosis with respect to all endpoints and Thymectomy also improved the prognosis but only for those patients without thymoma.

Myasthenia Gravis (MG): Epidemiological Data and Prognostic Factors

Univariate analysis and Kaplan‐Meier analysis showed that variables such as sex (female), age at onset (below 40 years), thymectomy, and histological diagnosis of thymic hyperplasia were significantly associated with complete stable remission, whereas on multivariate analysis only age at inception below 40 years and thymectomized myasthenia gravis were confirmed.

A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy

Thymectomy seemed to improve the course of the disease, mostly in patients operated on shortly after diagnosis and those with generalized mild-to-moderate disease and with a normally involuted thymus.

Prognosis of ocular myasthenia in Korea: A retrospective multicenter analysis of 202 patients

Myasthenia gravis: a long term follow-up study of Swedish patients with specific reference to thymic histology

The prognosis for the majority of patients with MG is favourable, irrespective of thymic histology, and the cause may be the use of immunomodulating therapy.

The natural course of myasthenia gravis: a long term follow up study.

  • H. Oosterhuis
  • Medicine
    Journal of neurology, neurosurgery, and psychiatry
  • 1989
A long term follow up study is presented of 73 patients with myasthenia gravis, living in Amsterdam between 1926 and 1965, and the evolution of their clinical state represents the natural course of MG.

Myasthenia gravis: presentation and outcome in 104 patients managed in a single institution

MG presents at a younger age among Saudi Arabs compared to other racial groups, and thymectomy conferred significant benefits towards achievement of remission.

Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients

Abstract One hundred consecutive patients with myasthenia gravis (MG) referred between 1985 and 1989 were analysed for epidemiological characteristics, evolution of early signs, delay in diagnosis,

Lifetime course of myasthenia gravis

The clinical course of MG was significantly influenced by age and gender, and these need special attention in managing patients, and novel drugs need to be developed to increase the number as well as normal functioning of the AChRs and other components of the neuromuscular system.